Search

Displaying results 6551 - 6560 of 10000 in total
  1. Drug

    Deramciclane

    go.drugbank.com/drugs/DB06512
    Investigational

    It antagonizes 5-HT2A receptors, agonizes 5-HT2C receptors, and functions as a GABA reuptake inhibitor. … Deramciclane differs from other anti anxiety medications in that it is not a benzodiazepine and so has a different structure and target.

    Categories: Serotonin Receptor Antagonists, Serotonin 5-HT2 Receptor Antagonists
  2. Drug

    Phosphoaminophosphonic Acid-Adenylate Ester

    go.drugbank.com/drugs/DB04395
    Experimental

    An analog of ATP, in which the oxygen atom bridging the beta to the gamma phosphate is replaced by a nitrogen atom. … It is a potent competitive inhibitor of soluble and membrane-bound mitochondrial ATPase and also inhibits ATP-dependent reactions of oxidative phosphorylation. [PubChem]

  3. Drug

    RO7284755

    go.drugbank.com/drugs/DB17527
    Investigational

    RO7284755 is an investigational cancer drug: it is a PD-1-targeted IL-2 variant antibody fusion protein. … RO7284755 is under investigation in clinical trial NCT04303858 (A Study to Evaluate Safety and Anti-tumor Activity of RO7284755 Alone or in Combination With Atezolizumab in Participants With Advanced And

  4. Drug

    Sonpiretigene isteparvovec

    go.drugbank.com/drugs/DB17844
    Investigational

    Sonpiretigene isteparvovec is an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy. … [L46676] Sonpiretigene isteparvovec consists of a fusion Adeno-associated virus (AAV) vector with three plasmids encoding opsins with spectrally-separated activation peaks.[L46681]

  5. Drug

    CIGB-258 peptide

    go.drugbank.com/drugs/DB15809
    Experimental

    CIGB-258 is a peptide that is immunoregulatory and derived from heat shock protein 60 of the cellular variant. … As of 2020, The Center for Genetic Engineering and Biotechnology (CIGB) in Havana, Cuba, is testing the treatment efficacy of this peptide in patients with COVID-19 who are under intensive therapy regimens

  6. Drug

    Glypromate

    go.drugbank.com/drugs/DB05633
    Experimental

    In December 2008, the company discontinued further development of the drug after it failed to show an observable effect. … Neuren Pharmaceuticals was developing Glypromate (glycine-proline glutamate), a naturally occurring small-molecule neuroprotectant derived from IGF-1 which inhibits caspase III dependent apoptosis, for

  7. Drug

    D-Proline

    go.drugbank.com/drugs/DB02853
    Experimental

    D-proline is an isomer of the naturally occurring amino acid, L-Proline. D-amino acids have been found in relatively high abundance in human plasma and saliva [A19262].

  8. Drug

    UB-612

    go.drugbank.com/drugs/DB16444
    Investigational

    The vaccine incorporates a strong S1-RBD component linked to a single chain fragment region (sFC) of a human IgG1, which facilitates cell attachment and acts as the principal neutralizing domain of the … This vaccine was designed to induce a broad immune response. It was able to reduce viral load and prevent COVID-19 infection in a mouse challenge model and in rhesus macaques[L30653, L30658].

  9. Drug

    Enrofloxacin

    go.drugbank.com/drugs/DB11404
    InvestigationalVet approved

    Enrofloxacin is an antibiotic agent from the fluoroquinolone family produced by the Bayer Corporation. Enrofloxacin is approved by the FDA for its veterinary use.

  10. Drug

    NTx-265

    go.drugbank.com/drugs/DB05649
    Investigational

    NTx-265 is a combination of two currently marketed large molecules designed to stimulate the growth and differentiation of neural stem cells in adults who have suffered a stroke – the second leading cause … In May 2006, biotechnology company Stem Cell Therapeutics started a Phase IIa study of NTx-265.